Urate oxidase (Uox) catalyses the oxidation of urate to allantoin and is used to reduce toxic urate accumulation during chemotherapy. X-ray structures of Uox with various inhibitors have been determined and yet the detailed catalytic mechanism remains unclear. Neutron crystallography can provide complementary information to that from X-ray studies and allows direct determination of the protonation states of the active-site residues and substrate analogues, provided that large, well-ordered deuterated crystals can be grown. Here, we describe a method and apparatus used to grow large crystals of Uox (Aspergillus flavus) with its substrate analogues 8-azaxanthine and 9-methyl urate, and with the natural substrate urate, in the presence and absence of cyanide. High-resolution X-ray (1.05 -1.20 Å ) and neutron diffraction data (1.9 -2.5 Å ) have been collected for the Uox complexes at the European Synchrotron Radiation Facility and the Institut Laue-Langevin, respectively. In addition, room temperature X-ray data were also collected in preparation for joint X-ray and neutron refinement. Preliminary results indicate no major structural differences between crystals grown in H 2 O and D 2 O even though the crystallization process is affected. Moreover, initial nuclear scattering density maps reveal the proton positions clearly, eventually providing important information towards unravelling the mechanism of catalysis.Keywords: urate oxidase; neutron and X-ray crystallography; crystal growth; phase diagram; H -D exchange; protonation states
INTRODUCTIONUrate oxidase (uricase or Uox, EC 1.7.3.3) is an enzyme involved in purine metabolism. It catalyses the oxidation of uric acid to 5-hydroxyisourate, a metastable intermediate, which is further degraded to allantoin. Humans and other primates lack a functional Uox, and therefore the final product of purine metabolism is uric acid. It has been speculated that this confers an evolutionary advantage to long-lived animals like primates owing to the anti-oxidant properties of urate, but the downside is that in certain conditions high urate levels (hyperuricaemia) may lead to crystallization of uric acid, as in gout.Uox from Aspergillus flavus has been commercialized by Sanofi-Aventis as a protein drug to treat hyperuraemic conditions such as the tumour lysis syndrome, but the catalytic mechanism of Uox is still poorly understood. Several X-ray structures have been solved for Uox in the complex with various uric acid analogues (Colloc'h et al. 1997(Colloc'h et al. , 2007Retailleau et al. 2004Retailleau et al. , 2005Gabison et al. 2006Gabison et al. , 2008, and a putative mechanism for the oxidation of uric acid has been proposed. However, many of the key questions are related to the protonation state of the substrate during the reaction. Uric acid has four potentially acidic protons; this gives rise to four different monoanions and six dianions. To be able to describe the mechanism, it is necessary to know which of the anions is the real substrate and how the hydrogen bonding netw...